Which has stronger earnings & valuation, MMED or BLFS?

MiniMed Group has higher revenue and earnings than BioLife Solutions. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MiniMed Group $2.99B 1.42 N/A N/A N/A BioLife Solutions $96.21M 13.25 -$4.59M -$0.08 N/A

BioLife Solutions (BLFS) Competitors

$26.10 0.00 (0.00%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$25.90 -0.20 (-0.77%)

As of 06/12/2026 07:58 PM Eastern

Compare

BLFS vs. LIVN, MMED, NVST, IRTC, and WRBY

Should you buy BioLife Solutions stock or one of its competitors? MarketBeat compares BioLife Solutions with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BioLife Solutions include LivaNova (LIVN), MiniMed Group (MMED), Envista (NVST), iRhythm Technologies (IRTC), and Warby Parker (WRBY). These companies are all part of the "medical equipment" industry.

How does BioLife Solutions compare to LivaNova?

BioLife Solutions (NASDAQ:BLFS) and LivaNova (NASDAQ:LIVN) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, valuation, risk, media sentiment and analyst recommendations.

93.2% of BioLife Solutions shares are held by institutional investors. Comparatively, 97.6% of LivaNova shares are held by institutional investors. 2.2% of BioLife Solutions shares are held by insiders. Comparatively, 0.4% of LivaNova shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

LivaNova has a net margin of 7.48% compared to BioLife Solutions' net margin of -2.80%. LivaNova's return on equity of 16.48% beat BioLife Solutions' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioLife Solutions	-2.80%	1.81%	1.65%
LivaNova	7.48%	16.48%	7.59%

BioLife Solutions presently has a consensus price target of $32.00, suggesting a potential upside of 22.61%. LivaNova has a consensus price target of $79.38, suggesting a potential downside of 0.02%. Given BioLife Solutions' higher possible upside, equities research analysts plainly believe BioLife Solutions is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioLife Solutions	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
LivaNova	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.67

BioLife Solutions has a beta of 2, indicating that its share price is 100% more volatile than the broader market. Comparatively, LivaNova has a beta of 0.88, indicating that its share price is 12% less volatile than the broader market.

BioLife Solutions has higher earnings, but lower revenue than LivaNova. BioLife Solutions is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioLife Solutions	$96.21M	13.25	-$4.59M	-$0.08	N/A
LivaNova	$1.39B	3.14	-$242.47M	$1.95	40.71

In the previous week, LivaNova had 6 more articles in the media than BioLife Solutions. MarketBeat recorded 7 mentions for LivaNova and 1 mentions for BioLife Solutions. BioLife Solutions' average media sentiment score of 1.88 beat LivaNova's score of 0.80 indicating that BioLife Solutions is being referred to more favorably in the media.

Company	Overall Sentiment
BioLife Solutions	Very Positive
LivaNova	Positive

Summary

LivaNova beats BioLife Solutions on 10 of the 16 factors compared between the two stocks.

How does BioLife Solutions compare to MiniMed Group?

MiniMed Group (NASDAQ:MMED) and BioLife Solutions (NASDAQ:BLFS) are both medical equipment companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and institutional ownership.

MiniMed Group has higher revenue and earnings than BioLife Solutions.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiniMed Group	$2.99B	1.42	N/A	N/A	N/A
BioLife Solutions	$96.21M	13.25	-$4.59M	-$0.08	N/A

In the previous week, MiniMed Group had 3 more articles in the media than BioLife Solutions. MarketBeat recorded 4 mentions for MiniMed Group and 1 mentions for BioLife Solutions. BioLife Solutions' average media sentiment score of 1.88 beat MiniMed Group's score of 0.47 indicating that BioLife Solutions is being referred to more favorably in the news media.

Company	Overall Sentiment
MiniMed Group	Neutral
BioLife Solutions	Very Positive

MiniMed Group presently has a consensus target price of $21.33, suggesting a potential upside of 40.72%. BioLife Solutions has a consensus target price of $32.00, suggesting a potential upside of 22.61%. Given MiniMed Group's stronger consensus rating and higher probable upside, analysts plainly believe MiniMed Group is more favorable than BioLife Solutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiniMed Group	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73
BioLife Solutions	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

19.7% of MiniMed Group shares are owned by institutional investors. Comparatively, 93.2% of BioLife Solutions shares are owned by institutional investors. 2.2% of MiniMed Group shares are owned by insiders. Comparatively, 2.2% of BioLife Solutions shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

MiniMed Group has a net margin of 0.00% compared to BioLife Solutions' net margin of -2.80%. BioLife Solutions' return on equity of 1.81% beat MiniMed Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiniMed Group	N/A	N/A	N/A
BioLife Solutions	-2.80%	1.81%	1.65%

Summary

MiniMed Group and BioLife Solutions tied by winning 6 of the 12 factors compared between the two stocks.

How does BioLife Solutions compare to Envista?

Envista (NYSE:NVST) and BioLife Solutions (NASDAQ:BLFS) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, profitability, valuation, earnings, institutional ownership and risk.

Envista has a net margin of 2.41% compared to BioLife Solutions' net margin of -2.80%. Envista's return on equity of 7.11% beat BioLife Solutions' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Envista	2.41%	7.11%	3.91%
BioLife Solutions	-2.80%	1.81%	1.65%

Envista has higher revenue and earnings than BioLife Solutions. BioLife Solutions is trading at a lower price-to-earnings ratio than Envista, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Envista	$2.72B	1.47	$47M	$0.41	59.86
BioLife Solutions	$96.21M	13.25	-$4.59M	-$0.08	N/A

93.2% of BioLife Solutions shares are owned by institutional investors. 1.0% of Envista shares are owned by company insiders. Comparatively, 2.2% of BioLife Solutions shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Envista currently has a consensus price target of $28.67, suggesting a potential upside of 16.80%. BioLife Solutions has a consensus price target of $32.00, suggesting a potential upside of 22.61%. Given BioLife Solutions' higher probable upside, analysts clearly believe BioLife Solutions is more favorable than Envista.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Envista	0 Sell rating(s)	9 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40
BioLife Solutions	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, BioLife Solutions had 1 more articles in the media than Envista. MarketBeat recorded 1 mentions for BioLife Solutions and 0 mentions for Envista. BioLife Solutions' average media sentiment score of 1.88 beat Envista's score of 0.50 indicating that BioLife Solutions is being referred to more favorably in the news media.

Company	Overall Sentiment
Envista	Positive
BioLife Solutions	Very Positive

Envista has a beta of 0.88, meaning that its stock price is 12% less volatile than the broader market. Comparatively, BioLife Solutions has a beta of 2, meaning that its stock price is 100% more volatile than the broader market.

Summary

Envista beats BioLife Solutions on 8 of the 15 factors compared between the two stocks.

How does BioLife Solutions compare to iRhythm Technologies?

iRhythm Technologies (NASDAQ:IRTC) and BioLife Solutions (NASDAQ:BLFS) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, dividends, media sentiment, valuation, risk and institutional ownership.

In the previous week, iRhythm Technologies had 4 more articles in the media than BioLife Solutions. MarketBeat recorded 5 mentions for iRhythm Technologies and 1 mentions for BioLife Solutions. BioLife Solutions' average media sentiment score of 1.88 beat iRhythm Technologies' score of 1.11 indicating that BioLife Solutions is being referred to more favorably in the news media.

Company	Overall Sentiment
iRhythm Technologies	Positive
BioLife Solutions	Very Positive

iRhythm Technologies presently has a consensus target price of $187.38, suggesting a potential upside of 64.88%. BioLife Solutions has a consensus target price of $32.00, suggesting a potential upside of 22.61%. Given iRhythm Technologies' stronger consensus rating and higher possible upside, equities research analysts clearly believe iRhythm Technologies is more favorable than BioLife Solutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iRhythm Technologies	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.94
BioLife Solutions	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

BioLife Solutions has a net margin of -2.80% compared to iRhythm Technologies' net margin of -3.53%. BioLife Solutions' return on equity of 1.81% beat iRhythm Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iRhythm Technologies	-3.53%	-10.26%	-1.39%
BioLife Solutions	-2.80%	1.81%	1.65%

iRhythm Technologies has a beta of 1.27, indicating that its stock price is 27% more volatile than the broader market. Comparatively, BioLife Solutions has a beta of 2, indicating that its stock price is 100% more volatile than the broader market.

BioLife Solutions has lower revenue, but higher earnings than iRhythm Technologies. BioLife Solutions is trading at a lower price-to-earnings ratio than iRhythm Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iRhythm Technologies	$747.14M	5.00	-$44.55M	-$0.86	N/A
BioLife Solutions	$96.21M	13.25	-$4.59M	-$0.08	N/A

93.2% of BioLife Solutions shares are held by institutional investors. 1.0% of iRhythm Technologies shares are held by insiders. Comparatively, 2.2% of BioLife Solutions shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

BioLife Solutions beats iRhythm Technologies on 10 of the 17 factors compared between the two stocks.

How does BioLife Solutions compare to Warby Parker?

BioLife Solutions (NASDAQ:BLFS) and Warby Parker (NYSE:WRBY) are both medical equipment companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, media sentiment, institutional ownership, dividends, profitability and risk.

BioLife Solutions presently has a consensus price target of $32.00, indicating a potential upside of 22.61%. Warby Parker has a consensus price target of $29.50, indicating a potential upside of 12.07%. Given BioLife Solutions' higher probable upside, research analysts clearly believe BioLife Solutions is more favorable than Warby Parker.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioLife Solutions	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Warby Parker	0 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.64

In the previous week, Warby Parker had 4 more articles in the media than BioLife Solutions. MarketBeat recorded 5 mentions for Warby Parker and 1 mentions for BioLife Solutions. BioLife Solutions' average media sentiment score of 1.88 beat Warby Parker's score of 0.33 indicating that BioLife Solutions is being referred to more favorably in the media.

Company	Overall Sentiment
BioLife Solutions	Very Positive
Warby Parker	Neutral

93.2% of BioLife Solutions shares are held by institutional investors. Comparatively, 93.2% of Warby Parker shares are held by institutional investors. 2.2% of BioLife Solutions shares are held by insiders. Comparatively, 16.8% of Warby Parker shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Warby Parker has higher revenue and earnings than BioLife Solutions. BioLife Solutions is trading at a lower price-to-earnings ratio than Warby Parker, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioLife Solutions	$96.21M	13.25	-$4.59M	-$0.08	N/A
Warby Parker	$871.91M	3.23	$1.64M	$0.02	1,316.20

BioLife Solutions has a beta of 2, meaning that its stock price is 100% more volatile than the broader market. Comparatively, Warby Parker has a beta of 1.96, meaning that its stock price is 96% more volatile than the broader market.

Warby Parker has a net margin of 0.15% compared to BioLife Solutions' net margin of -2.80%. Warby Parker's return on equity of 2.30% beat BioLife Solutions' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioLife Solutions	-2.80%	1.81%	1.65%
Warby Parker	0.15%	2.30%	1.18%

Summary

Warby Parker beats BioLife Solutions on 10 of the 15 factors compared between the two stocks.

Get BioLife Solutions News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BLFS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BLFS vs. The Competition

Export

Metric	BioLife Solutions	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.28B	$8.31B	$6.53B	$12.05B
Dividend Yield	N/A	2.50%	2.67%	5.66%
P/E Ratio	-326.21	15.64	23.99	24.42
Price / Sales	13.25	7.06	511.38	110.47
Price / Cash	113.98	17.44	27.48	37.92
Price / Book	3.38	3.62	10.65	6.82
Net Income	-$4.59M	$224.06M	$3.57B	$337.56M
7 Day Performance	N/A	-1.40%	0.58%	1.17%
1 Month Performance	25.72%	4.39%	1.54%	3.16%
1 Year Performance	18.47%	-0.88%	25.40%	30.58%

BioLife Solutions Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BLFS BioLife Solutions	3.3514 of 5 stars	$26.10 flat	$32.00 +22.6%	+18.5%	$1.28B	$96.21M	N/A	440	Positive News Gap Up
LIVN LivaNova	1.7656 of 5 stars	$77.43 +3.5%	$79.38 +2.5%	+73.5%	$4.22B	$1.39B	39.39	3,300
MMED MiniMed Group	4.3966 of 5 stars	$15.19 +2.1%	$21.33 +40.4%	N/A	$4.22B	$2.99B	N/A	8,000
NVST Envista	2.4162 of 5 stars	$24.18 +3.2%	$28.83 +19.2%	+33.1%	$3.89B	$2.72B	58.36	12,000
IRTC iRhythm Technologies	4.3412 of 5 stars	$110.04 +2.6%	$189.69 +72.4%	-21.0%	$3.59B	$747.14M	N/A	2,400	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BLFS) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioLife Solutions (BLFS) Competitors

BLFS vs. LIVN, MMED, NVST, IRTC, and WRBY

How does BioLife Solutions compare to LivaNova?

Summary

How does BioLife Solutions compare to MiniMed Group?

Summary

How does BioLife Solutions compare to Envista?

Summary

How does BioLife Solutions compare to iRhythm Technologies?

Summary

How does BioLife Solutions compare to Warby Parker?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BLFS vs. The Competition

BioLife Solutions Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioLife Solutions (BLFS) Competitors

BLFS vs. LIVN, MMED, NVST, IRTC, and WRBY

How does BioLife Solutions compare to LivaNova?

Do institutionals & insiders hold more shares of BLFS or LIVN?

Is BLFS or LIVN more profitable?

Do analysts rate BLFS or LIVN?

Which has more risk & volatility, BLFS or LIVN?

Which has higher earnings & valuation, BLFS or LIVN?

Does the media prefer BLFS or LIVN?

Summary

How does BioLife Solutions compare to MiniMed Group?

Which has stronger earnings & valuation, MMED or BLFS?

Does the media prefer MMED or BLFS?

Do analysts recommend MMED or BLFS?

Do insiders & institutionals hold more shares of MMED or BLFS?

Is MMED or BLFS more profitable?

Summary

How does BioLife Solutions compare to Envista?

Is NVST or BLFS more profitable?

Which has higher valuation & earnings, NVST or BLFS?

Do insiders and institutionals hold more shares of NVST or BLFS?

Do analysts prefer NVST or BLFS?

Does the media favor NVST or BLFS?

Which has more volatility & risk, NVST or BLFS?

Summary

How does BioLife Solutions compare to iRhythm Technologies?

Does the media refer more to IRTC or BLFS?

Do analysts prefer IRTC or BLFS?

Is IRTC or BLFS more profitable?

Which has more risk and volatility, IRTC or BLFS?

Which has preferable earnings and valuation, IRTC or BLFS?

Do institutionals & insiders hold more shares of IRTC or BLFS?

Summary

How does BioLife Solutions compare to Warby Parker?

Do analysts rate BLFS or WRBY?

Does the media prefer BLFS or WRBY?

Do institutionals and insiders hold more shares of BLFS or WRBY?

Which has better earnings and valuation, BLFS or WRBY?

Which has more volatility & risk, BLFS or WRBY?

Is BLFS or WRBY more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BLFS vs. The Competition

BioLife Solutions Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools